Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.
Cancer; Tumour immunology
Garralda E, Laurie SA, Seymour L, de Vries EGE. Towards evidence-based response criteria for cancer immunotherapy. Nat Commun. 2023 May 24;14:3001.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/9953
This item appears in following collections
The following license files are associated with this item: